PAVmed Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lishan Aklog
- Full Time Employees
- 39
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- One Grand Central Place New York City NY United States of America 10165
- IPO Date
- Jul 27, 2016
- CIK
- 0001624326
- Website
- pavmed.com
- Similar Companies
- Business
- PAVmed Inc. PAVmed Inc. (Nasdaq: PAVM) is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors; its primary businesses focus on cancer prevention diagnostics through subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD), which markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device as the first commercial tools for widespread early detection of esophageal precancer; enhanced personalized cancer care via subsidiary Veris Health Inc., which provides remote patient monitoring through the Veris Cancer Care Platform utilizing implantable biologic sensors, wireless communication, connected external devices, and an implantable physiological monitor implanted alongside chemotherapy ports; and an incubator unit PMX advancing pipeline technologies including the PortIO long-term vascular access device, EsoCure endoscopic esophageal ablation system, and CarpX percutaneous carpal tunnel treatment device. Founded in 2014 and headquartered at 360 Madison Avenue, 25th Floor, New York, New York, the company targets healthcare systems, clinicians, patients, and at-risk populations such as firefighters and cancer patients primarily in the United States through shared-services infrastructure enabling rapid resource deployment across subsidiaries. Recent developments include Veris Health launching the commercial phase of its strategic partnership with The Ohio State University Comprehensive Cancer Center—James Cancer Hospital, advancing electronic health record integration and deploying the Veris Cancer Care Platform while relaunching implantable physiological monitor development toward a planned 2026 FDA 510(k) submission; PAVmed signing a letter of intent with Duke University to license groundbreaking endoscopic esophageal imaging technology; Lucid Diagnostics securing a notice of allowance for a key patent on its EsoGuard test methodology, launching the first EsoGuard Mobile Test Unit, and expanding direct contracting initiatives including events for firefighters and former NFL players; Veris Health receiving a $1.8 million NIH grant to optimize its platform for underserved cancer patients; and the company launching wholly-owned incubator PMX in a joint venture with Hatch Medical to complete development and commercialization of PortIO, EsoCure, and CarpX.
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Will PAVmed Inc. (PAVM) Report Negative Earnings Next Week? What You Should Know
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
PAVmed (NASDAQ:PAVM) Shares Pass Below 50-Day Moving Average – Time to Sell?
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch
Treace Medical Concepts (NASDAQ:TMCI) and PAVmed (NASDAQ:PAVM) Head-To-Head Survey
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026